Keywords: Pernix Therapeutics, Somaxon Pharma, M&A, Silenor
Pernix Thera rescues struggling Somaxon with stock deal worth $25 million
Article | 12 December 2012
Troubled US drugmaker Somaxon Pharmaceuticals (Nasdaq: SOMX) saw its shares leap around 85% to $2.74 yesterday morning, when it was revealed that ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
